Evidence map›Paper›PMID 26040453›Full record

Trial reportRadiation oncology (London, England)2015

Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.

Bixiu Wen, Luning Zhang, Chengtao Wang, Rong Huang, Haihua Peng, Tian Zhang, Jun Dong, Weiwei Xiao, Zhifan Zeng, Mengzhong Liu and 1 more

Abstract readClinical TrialComparative Study
In one paragraph

Trial report in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bixiu WenDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. wenbix@mail.sysu.edu.cn.
Luning ZhangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. zhangln@sysc.org.cn.
Chengtao WangDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. wangcht5@mail.sysu.edu.cn.
Rong HuangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. huangrong@sysucc.org.cn.
Haihua PengDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. phhnihao@126.com.
Tian ZhangDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. zhangtian62@gmail.com.
Jun DongDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. dongjun2201@163.com.
Weiwei XiaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. xiaoww@sysucc.org.cn.
Zhifan ZengDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. zengzf@sysucc.org.cn.
Mengzhong LiuDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. liumz@sysucc.org.cn.
Yuanhong GaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. gaoyh@mail.sysu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate prognostic significance of clinical and pathological stages in patients with locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy (neo-CRT) and total mesorectal excision. PATIENTS AND

methods210 patients with locally advanced rectal carcinoma (cT3-4 or cN+) treated with neo-CRT followed by total mesorectal excision. Treatment outcomes were compared according to clinical and pathological stage. Overall survival (OS), disease free survival (DFS) among patients with different clinical stage and pathological stage after neo-CRT.

resultsThe median follow-up time was 47 months (range, 14-98 months). Clinical T stage was associated with 5 year OS (p = 0.042) and 5 year DFS (p = 0.014) while clinical N stage was not associated with 5 year OS (p = 0.440), 5 year DFS (p = 0.711). Pathological T stage was associate with 5 year OS (p = 0.001) and 5 year DFS (p = 0.046); and N stage was associated with 5 year OS (p = 0.001), 5 year DFS (p = 0.002). The pathological stage was further classified into three groups: ypT0-2N0 in 91 patients (43.3 %), ypT3-4N0 in 69 patients (32.9 %) and ypT0-4N+ in 50 patients (23.8 %). While pathological stage (ypT0-2 vs ypT3-4N0 vs ypT0-4N+) was associated with 5 year OS (87.9 %, 75.5 %, 56.7 %, p = 0.000), 5 year DFS (74.5 %, 77.4 %, 50.5 %, p = 0.003). Multivariate analysis showed that ypN stage was an independent prognostic factor for patients 5 year DFS.

conclusionsPathological stage is strongly associated with treatment outcomes in patients with locally advanced rectal carcinoma treated with neo-CRT followed by total mesorectal excision, which may be used as guidance for further individualized treatment.

Indexed as

ChemoradiotherapyNeoadjuvant TherapyRadiotherapy, ConformalAdenocarcinomaAdolescentAdultAgedAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCombined Modality TherapyDeoxycytidineDisease-Free SurvivalFemaleFluorouracilHumansAntimetabolites, AntineoplasticCapecitabineDeoxycytidineFluorouracilLeucovorinOrganoplatinum CompoundsOxaloacetates

Identifiers

PMID26040453
PMCPMC4490617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.